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Herein, we report the identification of a unique HIV-1 integrase (IN)
inhibitor-binding site using photoaffinity labeling and mass spec-
trometric analysis. We chemically incorporated a photo-activatable
benzophenone moiety into a series of coumarin-containing IN
inhibitors. A representative of this series was covalently photo-
crosslinked with the IN core domain and subjected to HPLC puri-
fication. Fractions were subsequently analyzed by using MALDI-MS
and electrospray ionization (ESI)-MS to identify photo-crosslinked
products. In this fashion, a single binding site for an inhibitor
located within the tryptic peptide 128AACWWAGIK136 was identi-
fied. Site-directed mutagenesis followed by in vitro inhibition
assays resulted in the identification of two specific amino acid
residues, C130 and W132, in which substitutions resulted in a
marked resistance to the IN inhibitors. Docking studies suggested
a specific disruption in functional oligomeric IN complex formation.
The combined approach of photo-affinity labelingMS analysis
with site-directed mutagenesismolecular modeling is a powerful
approach for elucidating inhibitor-binding sites of proteins at the
atomic level. This approach is especially important for the study of
proteins that are not amenable to traditional x-ray crystallography
and NMR techniques. This type of structural information can help
illuminate processes of inhibitor resistance and thereby facilitate
the design of more potent second-generation inhibitors.
drug design  mass spectrometry  photoaffinity labeling
HIV-1 integrase (IN) mediates the insertion of viral DNA intothe host genome. This process occurs through two separate
events, both catalyzed by IN. In the 3-processing reaction, IN
cleaves a dinucleotide adjacent to a conserved CA on each terminus
of the reverse-transcribed viral DNA. This cleavage results in two
3 hydroxyl groups that are used for a subsequent nucleophilic
attack. IN then inserts this DNA product into the host genome in
the second reaction, termed strand transfer (1, 2). IN reactions can
be carried out in vitro by using purified protein, a DNA substrate
with ends mimicking the U3 or U5 viral DNA termini, and Mg2
or Mn2 as a cofactor (3).
Structural information detailing the association between IN and
inhibitors under development is of enormous therapeutic impor-
tance. Knowledge of key amino acid residues involved in the
binding of potential drugs, and therefore which residues are likely
to mutate under therapeutic pressure, would inevitably help re-
searchers stay one step ahead of drug-resistant viral strains. A
co-crystal structure of one of our inhibitors was previously solved
with the ASV-IN (4, 5). This complex was subsequently used as a
surrogate structure to discover IN inhibitors through high-
throughput docking studies (6). Thus far, only two examples of
co-crystal structures of HIV-1 IN core in complex with inhibitors
have been reported (7, 8). Despite our own repeated attempts,
solving co-crystal structures of IN with our potent inhibitors has
failed. This paucity of structural information necessitates a need to
seek alternative technologies to obtain reliable information at the
atomic level.
The use of affinity-labeled inhibitors to covalently modify the site
of interaction and subsequent analysis of the protein have been very
effective in providing useful information about inhibitor binding for
a multitude of therapeutic target proteins. Application of this
approach to IN has elucidated a small number of inhibitor-binding
sites to atomic resolution. Two separate studies have used this
approach to map different nucleotide inhibitor-binding sites of IN.
The first used an AZT analog for photo-affinity labeling and
proteolytic mapping to identify amino acid residues K156, K159,
and K160 as the key residues involved in nucleotide binding (9).
Mutational analysis confirmed their involvement by decreasing
photo-crosslinking selectively. The second study identified residue
K244 as a possible nucleotide analog-binding site (10). Recently,
K173 was identified to selectively interact with acetylated chicoric
acid (11).
Coumarins represent a potent class of IN inhibitors that do not
contain a catechol moiety. Previous catechol-containing IN inhib-
itors were highly cytotoxic, rendering therapeutic development
impractical (12). Certain hydroxycoumarin analogues within this
class also exhibit antiviral activity (13). Compound 1 inhibited IN
at an IC50  1.5 M and inhibited disintegration activity of the
catalytic core domain (IN50–212) at a concentration of 15 M. This
result provides evidence that compound 1 binds the catalytic core
domain, and binding this region alone is responsible for inhibition
activity. Compound 1 also exhibits antiviral activity (13). Subse-
quent structure-activity relationship (SAR) studies were performed
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Fig. 1. Structures of earlier antiviral hydroxycoumarin compound 1 and the
unmodified compound 2, with the benzophenone-linked coumarins (com-
pounds 3–5) and positive control compound 6.
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to define the minimal chemical features of compound 1 required for
inhibitory activity (14). In the simplest case, the SAR deconstruc-
tion resulted in the generation of compound 2. Compound 2, with
the removal of two coumarin units, exhibited a reduction in
potency, with IC50 values of 43.4  23.7 M and 38.8  25.9 M
for 3-processing and strand transfer, respectively (14). Compound
2 represents the unmodified parent compound for the benzophe-
none-linked IN inhibitors 3–5. Chemical structures of compounds
1 and 2, along with the inhibitors used in this study, are depicted in
Fig. 1.
Here, we report the binding site characterization of a couma-
rin-containing IN inhibitor (compound 3; Fig. 1). Compound 3
contains a photo-activatable benzophenone moiety, which was
then used to crosslink the inhibitor to its binding site. Subsequent
trypsin digest and MS analysis identified the peptide fragment
located in a region of IN never before implicated in inhibitor
binding. Four residues within the region of protein were chosen
for site-directed mutagenesis, by using both conservative and
nonconservative substitutions. Residues C130 and W132,
showed a marked resistance to the inhibitors when substituted.
On the basis of molecular modeling studies, we conclude that the
coumarins exhibit their inhibitory effects by causing a steric
obstruction at the dimer interface of IN. This obstruction
possibly leads to an arrest in the formation of an enzymatically
functional multimeric complex.
Results
Compound 3 Binds to the IN Core Domain at a Stoichiometric Ratio of
1:1. Chemical structures of IN inhibitors 3–5, conjugated to ben-
zophenone moieties, are depicted in Fig. 1. Benzophenone is an
ideal photo-affinity probe for selective protein labeling. It is acti-
vated at wavelengths between 350 and 360 nm, a range that avoids
damage to the target protein. Once activated, it alkylates the protein
backbone (for review, see ref. 15). IC50 values for the unmodified
compound 2 (14) are in agreement with values obtained for
benzophenone-linked analogues 3–5 using WT IN, indicating that
the benzophenone moiety does not affect compound binding.
Additionally, the benzophenone moiety alone did not show any
inhibitory activity at concentrations up to 1 mM (data not shown).
We used compound 3 as a representative inhibitor for crosslinking
experiments. After crosslinking, the sample was analyzed by using
both MALDI-MS and electrospray ionization (ESI)-MS. Fig. 2A
shows a representative MALDI-MS spectrum of the IN core:com-
pound 3 complex. A comparison of IN core domain alone with the
IN core:compound 3 complex is shown in Fig. 2B. The ESI-MS
technique revealed that the molecular weight shift corresponds to
a single molecule of compound 3. This result indicates that the
stoichiometric ratio of IN core domain to inhibitor is 1:1 and
provides direct evidence for a single binding site.
Compound 3 Interacts with a Region of IN Never Before Implicated in
Inhibitor Binding. Tryptic digestion of the complex was performed
to narrow down which peptide region of the IN core domain
interacts with the inhibitor. Resulting peptides exhibiting a differ-
ence in UV absorbance compared with control were purified, and
the fragment (T7) 128AACWWAGIK136 was identified as the site
of photo-crosslinking. The predicted molecular weight of T7 is
1,004.49, which, crosslinked to compound 3, gives a molecular
weight of 1,520.61. Fig. 2C depicts the ESI-MS spectrum of the IN
tryptic peptide T7 crosslinked to compound 3. This region provides
a unique drug-binding site that can be exploited in the design of new
IN inhibitors.
Catalytic Activities of IN Mutants. Four different residues were
chosen for site-directed mutagenesis: C130, W131, W132, and
Fig. 2. Compound 3 binds to IN at a 1:1 ratio. (A) MALDI-TOF of an HPLC fraction containing the IN core complexed to compound 3 along with the IN core domain
alone (control). (B) Two ESI-MS spectra showing the IN core domain alone, and complexed with compound 3. (C) ESI-MS spectrum showing the tryptic peptide
T7 bound to one molecule of compound 3.









K136. We also selected a residue (Q148) outside the implicated
peptide to be included in the inhibition assays. Multiple substitu-
tions at position W132 were constructed to obtain a mutant with
both 3-processing and strand transfer catalytic activities. This effort
resulted in the production of three nonconservative and one
conservative substitution. Mutants were synthesized in the context
of an IN double mutant (F185KC280S) that exhibits increased
solubility and that has been previously shown to be as catalytically
active as the WT enzyme in vitro (16). All compounds showed
similar inhibition profiles in the WT IN (data not shown) as well as
the soluble double mutant. Fig. 6, which is published as supporting
information on the PNAS web site, shows a representative gel
depicting the enzymatic activities of the mutant IN proteins,
including the soluble double mutant, versus the WT IN. Table 1 lists
the relative activities of each mutant. With the exception of Q148A,
all of the 3-processing activities of the mutant IN proteins were
fairly robust. On the other hand, strand transfer activity of the
mutants varied significantly. The nonconservative substitutions
made at position W132 abolished strand transfer activity of these IN
mutants. Experiments using other metal cofactors (Ca2 and Zn2)
in the reaction buffer failed to restore activity (data not shown).
Additionally, both C130S and Q148A exhibited diminished strand
transfer capabilities (10–40%).
Substitutions at IN Residues C130 and W132 Confer Resistance to
Inhibitors 3–5. Inhibition of IN-mediated catalytic activities by all
compounds is shown in Fig. 3, with IC50 values given in Table 2. We
used the IN inhibitor 6 (17) as the positive control (Fig. 1).
Compound 6 is structurally dissimilar to the coumarin set and
therefore is predicted to have a different binding site. A comparison
of the mutant IN inhibition profiles with WT indicates two residues,
C130 and W132, that are critical for the inhibitory effects of the
coumarins. In the case of the C130 substitutions, resistance was
observed in the serine substitution mutant, but not the alanine
mutant. C130A displayed a similar inhibition profile to that of WT.
C130S showed an increased resistance specific for 3-processing
only. C130S showed an 2-fold increase in 3-processing IC50 values
for compounds 3 and 4 (P  0.001 for each, respectively) and an
3-fold increase in the IC50 value for compound 5 (P  0.001).
Nonconservative substitutions at position W132 generated a pro-
nounced decrease in inhibition of 3-processing activity by com-
pounds 3–5. The most radical substitution, from tryptophan to
glycine, created the most resistant IN protein to these inhibitors.
For 3-processing activity, the W132G mutant exhibited IC50 values
that increased nearly 4-fold for compound 3 (P  0.001), 5-fold for
compound 4 (P  0.001), and 3-fold for compound 5 (P  0.001).
The resistance was decreased to a certain degree for W132A, with
IC50 values increasing by 3-fold for compound 3 (P  0.001), close
to 2-fold for compound 4 (P  0.001), and an IC50 value one and
a half times that of WT for compound 5 (P  0.016). Resistance
decreased even more for the W132R mutant, with an IC50 value for
compound 3 (P  0.004) being one and a half times that of WT, and
with values for compound 4 (P  0.439) and compound 5 (P 
0.949) being quite similar to WT. None of the above W132 mutants
retained their ability to catalyze strand transfer, and therefore the
effects of each substitution on drug potency concerning this activity
could not be assessed. The last W132 mutant, which contained a
conservative tryptophan to tyrosine substitution, retained strand
transfer activity. All compounds exhibited inhibition profiles com-
parable with that of WT when tested with W132Y. After statistical
analysis, two of the nonconservative W132 substitutions (G and A)
and C130S showed significant mean IC50 value deviations for
3-processing activity when tested with compounds 3–5. W132R
showed significant deviations when tested with compound 3 only.
None of the mutants showed any significant mean IC50 value
deviations for 3-processing inhibition by the positive control,
compound 6. Concerning strand transfer inhibition, C130A (com-
pound 6), C130S (compounds 4–6), and W131G (compounds 5 and
6) each showed significant mean IC50 value deviations from WT.
All significant mean strand transfer IC50 values were lower than
WT. This finding indicates a possible increase in inhibitor suscep-
tibility of these mutants, or it may be linked to a reduction in basal
level strand transfer activity, concerning C130S and W131G. Re-
Table 1. Relative activities of integrase proteins











*Activity designation relative to WT: , 0–10%; , 10–40%; , 40–80%;
, 80–100%.
†F185KC280S soluble double mutant.
Fig. 3. Resistance to coumarins observed
in nonconservative W132 mutants and
C130S. Comparison of the IC50 values for IN
inhibitory compounds 3 (A), 4 (B), 5 (C), and
6 (D) in different mutants. 3-processing
values are indicated by open bars, whereas
strand transfer values are indicated by
filled bars.
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sistance to the coumarins compounds 3–5 in C130S and the
nonconservative W132 mutants was observed only for 3-processing
activity, not strand transfer. The absence of strand transfer resis-
tance may be linked to the successive nature (strand transfer activity
depends on prior 3-processing activity) of the in vitro IN assay. To
directly address the inhibitory effect of the coumarins on the strand
transfer activity, we tested compound 3 against WT, the soluble
double mutant, C130S, and W132G (representative of nonconser-
vative W132 mutants) using a 3-processed oligonucleotide sub-
strate. Compound 3 strand transfer IC50 values for each IN protein
were in general agreement with results obtained with the unproc-
essed substrate (Fig. 7, which is published as supporting information
on the PNAS web site). Calculated IC50 values of 17, 18, and 3.2 M
were obtained for WT, the soluble double mutant, and C130S,
respectively. This result demonstrates that the biased resistance
observed for these mutants is not an artifact of the IN in vitro assay.
The mutant W132G still did not retain strand transfer activity.
Docking Studies Show That Inhibitor 3 Binds Close to the Dimeric
Interface of the IN Core Domain. To distinguish key binding inter-
actions between the IN core domain, particularly with respect to the
peptide 128AACWWAGIK136 region and compound 3, we docked
the compound onto the IN core domain dimer (PDB 1BL3) (18)
carrying the WT sequence and two W132 mutations. Compound 3
binds to the peptide 128AACWWAGIK136 region on the surface of
the IN core domain in WT as well as the mutants W132G and
W132Y. The benzophenone moiety of compound 3 occupies an
area close to the backbone of amino acid residues A133 and G134.
This finding supports the formation of a covalent linkage between
the backbone of the peptide 128AACWWAGIK136 region and the
benzophenone moiety of 3 upon photo activation. The bound
conformation of 3 on the surface of the dimeric IN core domain is
shown in Fig. 4. A hypothetical tetrameric arrangement for cata-
lytically functional IN core domain formed from two dimeric core
domains is also depicted in Fig. 4. Compound 3 binds to the peptide
128AACWWAGIK136 and most likely disrupts the formation of a
catalytically functional tetrameric IN. From the analysis of IN
dimeric core domain crystal structure, it is observed that a part of
the peptide 128AACWWAGIK136 contributes to the interfacial
surface of the IN dimer. In particular, the amino acid residue W132
is buried in the interfacial surface and establishes a stacking
interaction with residue F181 from the other IN monomer (the
shortest interplanar atom–atom distance is 3.65 Å). The predicted
bound conformations of compound 3 on the core domain surface
of WT and IN mutants W132G and W132Y are shown in Fig. 8 a–c,
which is published as supporting information on the PNAS web site.
Compound 3 adopted a similar bound conformation on these three
core domain structures, suggesting that the coumarins still bind the
Table 2. Integrase proteins with IC50 values (M) for inhibitory compounds and corresponding P values* after comparison with WT
Compound WT C130A C130S W131G W132A W132G W132R W132Y K136R Q148A
3 Processing
3 27  3 31  3 62  11 18  2 80  8 97  3 47  7 21  4 25  2 16  2
(0.993)† (0.001) (0.446) (0.001) (0.001) (0.004) (0.882) (1.0) (0.286)
4 14  0 9  1 35  6 6  1 35  9 77  7 22  5 5  2 12  1 4  1
(0.872) (0.001) (0.46) (0.001) (0.001) (0.439) (0.352) (1.0) (0.187)
5 18  1 30  3 58  9 9  1 38  11 71  10 24  2 8  1 18  2 8  2
(0.322) (0.001) (0.614) (0.016) (0.001) (0.949) (0.558) (1.0) (0.502)
6 7  1 5  3 1  1 2  1 4  3 12  4 2  2 10  6 8  1 6  1
(0.974) (0.219) (0.278) (0.847) (0.479) (0.445) (0.983) (1.0) (0.999)
Strand transfer
3 18  3 24  5 12  4 19  3 NA‡ NA NA 18  1 21  6 23  9
(0.752) (0.761) (1.0) (1.0) (0.966) (0.87)
4 11  4 6  1 2  1 5  1 NA NA NA 6  1 14  6 4  2
(0.456) (0.034) (0.204) (0.448) (0.935) (0.180)
5 17  2 10  1 4  2 7  1 NA NA NA 13  4 16  7 8  2
(0.185) (0.005) (0.043) (0.815) (1.0) (0.061)
6 7  2 4  1 1  1 2  1 NA NA NA 6  1 7  1 5  1
(0.017) (0.001) (0.001) (0.539) (0.992) (0.139)
*P values generated by using a Tukey multiple comparison test, after a statistical test of variance (P  0.05). Mean IC50 values of three independent IN mutant
experiments were compared with that of the WT IC50 mean value (in triplicate) for each inhibitory compound.
†P values are in parentheses.
‡NA, not applicable. Strand transfer activity for nonconservative substitutions at position W132 was abolished. Therefore, IC50 values could not be obtained and
statistical analyses could not be conducted.
Fig. 4. Coumarins bind to a region that
may disrupt formation of active IN multim-
ers. Shown are symmetric dimers with a
tetrameric arrangement for a catalytically
functional IN core domain. Compound 3 is
shown in white ball and stick, the side
chains of the 128AACWWAGIK136 residues
are shown as green stick, the magenta and
yellow ribbon shows two IN monomers,
whereas red sticks and brown spheres rep-
resent the conserved DDE motif and Mg2
ion, respectively.









resistant IN mutants but are unable to inhibit 3-processing activity.
To gain further insight, we examined the activity of compound 3
against preassembled WT IN–DNA complexes in the presence of
Ca2. Ca2 facilitates IN–DNA complex formation without pro-
ceeding to enzymatic cleavage of the DNA (19, 20). The inhibitory
potency of compound 3 was drastically reduced against preas-
sembled IN–DNA complexes, 4-fold increase to an IC50  100
M for 3-processing only. The strand transfer IC50 value of
compound 3 decreased 2-fold to 6.3 M (Fig. 5). This result
supports our hypothesis that the coumarin compounds exhibit their
inhibitory mechanism of action through disruption of IN multimer
formation.
Antiretroviral Activity. Compounds 3–5 were found to inhibit HIV-
1(IIIB) replication in the presence of 0.2 gml S-1360 at EC50
values of 5.96, 6.47, and 3.46 gml for compounds 3, 4, and 5,
respectively, in MT-4 cells. Cytotoxicity was observed at 5- to 7-fold
higher concentrations [50% cytotoxic concentration (CC50) values:
28.7, 30.9, and 24.3 gml, respectively, in mock-infected MT-4
cells].
Discussion
We identified the peptide region 128AACWWAGIK136 of IN as the
binding site for a set of coumarins. This region is located on an
-helical segment adjacent to the IN dimer interface. An analogous
-helix contributes to the dimerization of the RuvC resolvase
protein, a holliday junction-specific endonuclease involved in ho-
mologous DNA recombination (21). Coumarins interact specifi-
cally with the peptide backbone of this region, potentially disrupting
the formation of active multimeric complexes of IN. The C130S and
nonconservative W132 substitutions create structural perturbations
that disrupt multimer formation and therefore the binding inter-
actions between these inhibitors and the peptide region 128AAC-
WWAGIK136 in the context of a multimeric IN structure. Structural
perturbations caused by C130S have been documented and pro-
posed to disrupt other processes, but not inhibitor binding (22–24).
Substitutions made at amino acid residue W131 (W131D and
W131E) have been shown to increase the solubility of IN fragments,
enhancing their ability to crystallize, without effecting protein
structure (25, 26). The mutant W131G exhibited no resistance to
the coumarins. After analysis of both of the two domain x-ray
crystal structures of IN (26, 27), a critical – stacking interaction
between W132 and F181 was observed between two IN monomers.
To our knowledge, no previous reports implicate F181 and W132
as important for any IN processes. Making conservative and
nonconservative amino acid substitutions at position W132, thereby
either retaining or abolishing the – stacking interaction between
the two residues, produced very interesting effects on IN pheno-
type. The conservative substitution, tryptophan to tyrosine, where
an aromatic ring system is retained, was the only W132 mutant that
preserved strand transfer activity. It seems that having an aromatic
ring for interaction with F181 on a complementary IN monomer is
crucial for the strand transfer reaction. Additionally, only the
W132Y mutant displayed an inhibition profile similar to that of
WT, suggesting that the – stacking interaction at the dimer
interface promotes IN multimer formation and optimal coumarin
inhibition. The nonconservative substitutions generated at position
W132 eliminate the – stacking interaction with F181 between
monomers, possibly creating structural defects that may arrest the
formation of fully functional IN multimers. This may be the reason
why the strand transfer activity is abolished, even though the ability
to conduct 3-processing is preserved, with, however, more resil-
ience to coumarin inhibition. Indeed current models and experi-
mental evidence on retroviral IN composition indicate that a
dimeric species may be sufficient for 3-processing, but a tetrameric
arrangement, stabilized through target DNA binding at the dimer–
dimer interface, is necessary for the integration process and more
relevant to the in vivo nucleo–protein complex (28, 29). Results on
avian sarcoma virus IN also suggest that tetramer formation is an
obligatory step that occurs during strand transfer catalysis (28). Our
results using compound 3 on ‘‘preassembled’’ IN–DNA complexes
also support the above sequential model for HIV-1 IN multimer
formation. Ca2-induced IN-DNA ‘‘preassembly’’ may constitute
the formation of only an IN dimer bound to the DNA substrate. The
addition of compound 3 afterward would be less effective on
3-processing, but still effective at inhibiting multimer formation,
and therefore strand transfer, once catalysis is initiated (Mn2 or
Mg2 addition) and multimerization is stimulated. Our results also
indicate the – stacking interaction at the dimer interface is an
additional requirement for multimerization (tetramerization) and
the integration process. We hypothesize that an aromatic ring
system at position 132 is required for formation of an active IN
multimer. The requirement of the – stacking interaction at the
dimer interface for strand transfer catalytic activity, but not 3-
processing, is an interesting observation. K136 is an exposed surface
residue. An arginine substitution at this position created no effect
on inhibitor binding. Q148 is located outside the coumarin-binding
peptide region (128–136). Q148A mutant IN proteins did not show
any severe resistance to these molecules.
In conclusion, we successfully identified an IN inhibitor-binding
site through photo-affinity labelingMS analysis and validated the
site through site-directed mutagenesis and in vitro assays. Concern-
ing IN mutants with increased resistance, IC50 values of the
coumarins increased from 2-fold up to 5-fold. The observed cou-
marin resistance at the protein level is consistent with other studies
on IN inhibitor resistance. A prior study examined HIV-1 viral
resistance to L-708,906 and S-1360, which are derivatives from the
diketo acid class of IN inhibitors. Although a 10-fold viral resistance
to these IN inhibitors was the observed phenotype, the correspond-
ing triple mutant (T66IL74MS230R) protein exhibited only 2- to
3-fold resistance in vitro to the same compounds (30). The couma-
rins interacted directly with the peptide backbone in the region
128AACWWAGIK136. This peptide is located at the dimer interface
of IN. We also located a – stacking interaction at the dimer
interface between W132 of this region and F181 on a separate
monomer that is critical for IN multimer structure and function.
Upon binding to the peptide backbone, the inhibitors are hypoth-
esized to disrupt the formation of active IN multimers. Substitutions
at amino acid positions that structurally alter IN multimer forma-
tion also exhibited resistance to the inhibitors in in vitro inhibition
assays using full-length IN.
Several molecules bearing the coumarin structural unit have
been reported to show activity against a variety of therapeutic
Fig. 5. Coumarins are less potent against Ca2-induced preassembled IN-
DNA complexes. Shown are the inhibitory effects of compound 3 on preas-
sembled WT IN complex. Concentration of compound 3 decreases successively
by a fraction of two-thirds from 100 M to 1.2 M.
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targets. Compounds 3–5 are among a class of coumarins that show
a range of inhibitory activities against IN (14). The extent of IN
inhibition, however, is directly correlated to definite structural
variations in each analogue. This observed structure-activity rela-
tionship (SAR) supports that compounds 3–5 selectively disrupt IN
catalytic activity and are specific for this enzyme (14). Early
hydroxycoumarins like the tetrameric compound 1 have shown
antiviral activity at 11.5 M (13). The compounds used in this study
inhibit HIV-1(IIIB) replication in the presence of 0.2 gml S-1360
at EC50 values of 5.96, 6.47, and 3.46 gml for compounds 3, 4, and
5, respectively, in MT-4 cells. Compound 3 does display excellent
activity in the presence of Mg2 (Fig. 9, which is published as
supporting information on the PNAS web site), although the
presence of polyethylene glycol (PEG) in the reaction buffer does
seem to affect activity. Compound 3 IC50 values in the absence of
PEG are 9  1 M and 4  1 M for 3-processing and strand
transfer, respectively. These values are significantly lower than
those obtained using Mn2 as a cofactor. With the inclusion of
PEG, compound 3 IC50 values for 3-processing and stand transfer
were 36 M and 6.8 M, respectively. This compound is less
effective against the 3-processing activity of IN in the presence of
Mg2 and PEG.
Members of the diketo acid class of compounds were the first
important developmental candidates suspected of binding the IN
active site. The V(D)J recombinase protein RAG12, which is
important for T and B cell development, has mechanistic similar-
ities to HIV-1 IN. Certain IN diketo inhibitors suspected to bind the
active site have the potential to interfere with RAG12 cellular
function, posing serious toxicity issues. Indeed, there has been a
report showing a member of the diketo acid class of IN inhibitors
that was able to inhibit RAG12 in vitro, although at a much higher
concentration than what is required for IN inhibition (31). With this
potential diketo acid nonspecificity in mind, the field has slightly
shifted focus on the more IN-exclusive naphthyridine carboxamide
class of inhibitors. Potential IN inhibitors designed to target the
binding site discovered here should exhibit effective multimer
disruption, affording a very different mechanism of action than
active site binding. Additionally, a cocrystal structure of the binding
domains of IN and lens-epithelium-derived growth factor
(LEDGF) (PDB 2B4J) (32), an important IN cellular cofactor
thought to facilitate chromatin tethering, has recently been re-
ported in the literature. The hotspots of protein–protein interaction
contained several critical contacts directly corresponding to our
identified inhibitor-binding site, including IN residues A128, A129,
W131, and W132. This independent result indicates that molecules
specifically designed to target the allosteric binding site presented
here may also disrupt LEDGF interaction in vivo. These converging
results highlight a legitimate allosteric binding site that will enable
high-resolution, structure-based drug design strategies to develop
small molecules with further selectivity and potency. The designed
molecules have the capability to exhibit two simultaneous inhibitory
mechanisms, disruption of HIV-1 IN-LEDGF cofactor interaction
and IN multimer formation.
Materials and Methods
Chemistry. The benzophenone moiety was chemically attached as
described (33).
Photoaffinity Labeling. The catalytic core domain of IN was used for
photo-crosslinking based on previous results demonstrating that
hydroxycoumarins inhibit disintegration activity of the IN catalytic
core domain (13). To form the protein–ligand complex, IN was
incubated with a 25 molar excess of compound 3 at a final protein
concentration of 1.3 	 105 M in a buffer containing 2.5 mM
MnCl2, 50 mM 2-mercaptoethanol, 0.2% CHAPS, and 33%
DMSO for 30 min at room temperature. The protein–ligand
complex was radiated for 30 min with UV (360 nm) at a 3-cm
distance at 4°C under the conditions described (34, 35).
For further details, see Supporting Materials and Methods, which
is published as supporting information on the PNAS web site.
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